In January, after the DermaSensor became the first artificial intelligence (AI)-enabled device cleared by the US Food and Drug Administration (FDA) to evaluate lesions suggestive of skin cancer, the ...

TALLAHASSEE, Fla.--(BUSINESS WIRE)--DermaSensor Inc., a health technology company equipping primary care physicians (PCPs) with a non-invasive device for evaluating suspicious skin lesions and a proud ...

Symmetrical—lesions appear to be distributed in a similar arrangement on differing sides of the body (Figure 3, see slideshow) Once the configuration and distribution has been determined, the next ...

Please provide your email address to receive an email when new articles are posted on . The device is a handheld tool that uses spectroscopy and algorithms to test worrisome skin lesions for cancer.

Dermatology Nursing. 2005;17(2):165-166. Dermatology Nursing Essentials: A Core Curriculum (2nd edition) was written to provide the reader with core knowledge about the specialty of dermatology ...